LBRX

At a glance

Lb Pharmaceuticals Inc (LBRX) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in New York, United States and has 49 employees. The company is worth $1.19B and trades at 367.4x its earnings of the last twelve months; the median for its sector is 24.3x. The share price is 26.8% below its 52-week high of $50.16. 3 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $8.41M. In that quarter, 2 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$1.19B

P/E

367.4x

Forward P/E

—

P/B

3.2x

Dividend yield

0.00%

Payout

—

EPS

$0.10

ROE

-50.00%

Profit margin

0.00%

Revenue growth

—

Beta

—

52-week high

$50.16

52-week low

$14.32

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• IE
  Israel Englander+ Added

  Millennium Management · Q2 2026
  $8.41M

  259.22K shares · 0.0% of portfolio
• 
  Ken Griffin− Reduced

  Citadel Advisors · Q2 2026
  $7.01M

  215.97K shares · 0.0% of portfolio
• TS
  Two Sigma+ Added

  Two Sigma Investments · Q2 2026
  $1.58M

  48.65K shares · 0.0% of portfolio

Fair price, seven ways

Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company